John A. Fallon MD - 18 May 2023 Form 4 Insider Report for COLLEGIUM PHARMACEUTICAL, INC (COLL)

Reporting relationship: Director
Issuer ticker: COLL
Reported as of: 18 May 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2023, 16:39:04 UTC
Prior SEC filing: 23 May 2022
Next SEC filing: 16 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Shirley R. Kuhlmann as Attorney-in-Fact for John A. Fallon, MD

Key filing fact

John A. Fallon MD filed Form 4 for COLLEGIUM PHARMACEUTICAL, INC (COLL) on 19 May 2023.

Key facts

This page summarizes John A. Fallon MD's Form 4 filing for COLLEGIUM PHARMACEUTICAL, INC (COLL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 May 2023, 16:39.

Change

Previous filing in this sequence was filed on 23 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

COLL transaction

Common Stock

Award

Transaction value: $0
Shares: +9,792
Change %: +26%
Price: $0.000000
Shares after: 47,150
Date: 18 May 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 18, 2024, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock.